Review of Adult and Pediatric Ocular Tumors and Ocular Toxicity: From Eyelid to Choroid

Tuesday, July 18, 2023, 6:00 PM - 8:00 PM, Zuckerman Research Center 417 E 68th St, New York, NY

This complimentary two-hour program will provide the latest information on new cancer drugs and how to identify ocular toxicity associated with them. Expert faculty from MSK will provide a refresher on pediatric and adult ocular tumors as well as a review of treatment advances in recent years. Lectures include:

• Ocular Side Effects of Cancer Medications (Julia Canestraro, OD)
• Ophthalmic Imaging to Distinguish Malignant from Non-Malignant Tumors (Jasmine H. Francis, MD)
• Update on Retinoblastoma (David H. Abramson, MD)
• Eyelid Tumors: Assessment and Approach to Management (David Della Rocca, MD)

This course is intended for Optometrists, primary eyecare providers, and residents. In-person and virtual registration available. Dinner will be provided for in-person attendees.

We invite attendees to join us live, in-person or virtually, for this program. The program will be held at Memorial Sloan Kettering's Zuckerman Research Center.

Zuckerman Research Center
417 East 68th Street, New York, NY
Parking | Get Directions

COPE CE Credits Available

Attendees interested in claiming COPE CE credits must first register for this course. After you have successfully registered, please update your Profile by selecting "My CME" in the navigation and then "Profile". Under profession, select "Optometrist" and then scroll down the page to enter your state and COPE license number (i.e.: NY 071823).

1. Diagnose ocular toxicity in patients on new classes of anti-cancer agents
2. Identify lid tumors and manage them appropriately
3. Accurately recognize choroidal tumors and manage them appropriately
4. Understand new techniques used to treat retinoblastoma

Registration is complimentary to attend this course. Please select the "Register" tab above to complete registration (please note that registration is required to attend).

In-person Registration

Dinner will be provided for in-person attendees. Please contact [email protected] at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

While MSK requests that institutional guests are vaccinated against COVID-19, we are no longer requiring proof of vaccination. Additional details, including our current Health and Safety Protocols, can be accessed on our Visiting Us page. If you are not feeling well or exhibiting any symptoms of COVID-19, please refrain from attending an in-person event at MSK and contact [email protected] as soon as possible.

Virtual Registration

The virtual option for this program will be delivered through Zoom. Access details, including a link to Zoom, are included in the confirmation email you receive after registration. They will also be emailed to you prior to the start of the course.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COPE CE Credits

This activity, COPE Activity Number #126060, is accredited by COPE for continuing education for optometrists.

Memorial Sloan Kettering Cancer Center is accredited by COPE to provide continuing education to optometrists.

Julia Canestraro, OD

David H. Abramson, MD

David Della Rocca, MD

Jasmine H. Francis, MD

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity. The content of this activity was planned and prepared independently by the administrator or provider without input from members of an ineligible company. 

Tuesday, July 18, 2023